Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

The framework for designing and executing comprehensive neurobehavioral assessments in preclinical models of Huntington’s Disease (HD) is centered on a tailored, data-driven strategy. This approach moves beyond standard functional screens to generate a robust data package suitable for IND submission. It requires specific behavioral assays, the integration of correlative histology, and the operational experience to manage complex, long-term in vivo programs under GxP conditions.

Quantifying Therapeutic Efficacy in Huntington’s Disease

A successful preclinical program for a potential gene therapy for Huntington’s Disease must generate quantitative, objective data demonstrating a clear link between the therapeutic intervention and a meaningful change in motor or cognitive function. A one-size-fits-all testing template does not exist for these programs.

An effective strategy is built on a deep understanding of the specific HD model and the mechanism of action of the therapeutic candidate, whether it is an AAV-delivered miRNA for huntingtin-lowering or a CRISPR-based gene editing system.

A Tailored Approach to Neurobehavioral Assessment

Our scientific approach involves designing a battery of tests that capture the complex symptomatology of HD progression in preclinical models. This provides a multi-dimensional view of therapeutic impact.

• Motor Function: We utilize automated rotarod systems to precisely measure deficits in motor coordination and balance over time. Grip strength meters provide objective data on progressive muscle weakness.

• Locomotor and Exploratory Activity: Open field tests are monitored via video tracking software to quantify parameters like total distance traveled, rearing frequency, and time spent in the center versus periphery, offering insights into general activity and anxiety-related behaviors.

• Cognitive Assessment: Depending on the specific model and sponsor goals, cognitive tests such as the Y-maze for spatial memory can be integrated into the study design to assess non-motor domains affected by HD.

Learn more about the infrastructure required for next-generation therapeutics in the full video: .

Integrating Histology for Correlative Analysis

Behavioral data is most powerful when supported by physical evidence of therapeutic effect at the cellular level. At the conclusion of the in vivo phase, we perform comprehensive histological analysis. This includes quantifying transgene expression, assessing neuronal viability, and measuring the reduction of mutant huntingtin (mHTT) protein aggregates in target brain regions. This integrated analysis strengthens the overall data package by directly linking functional recovery to the therapy’s biological activity.

Proven Vector Experience for IND-Enabling Programs

Our deep experience with viral vectors informs every aspect of study design. The foundational work demonstrating that novel AAV vectors can achieve long-term correction of complex metabolic defects (PMID: 15170737) provides a strong basis for our work in other challenging indications. This knowledge of how to achieve durable, functional outcomes with AAV-based systems is directly applicable to designing therapies for neurodegenerative disorders.

Further work confirming the efficacy of AAV serotypes in sophisticated translational models (PMID: 22985273) reinforces the value of selecting the correct vector and study design to achieve significant and lasting therapeutic benefit. This history provides the intelligence needed to de-risk programs and build a compelling case for clinical translation.

Animal Welfare and Program Oversight

All studies are conducted in strict compliance with AAALAC and USDA guidelines. We are committed to the 3Rs principle (Replacement, Reduction, and Refinement) as a core component of our animal welfare program. This includes enhanced housing conditions and social enrichment programs to ensure the well-being of all animals throughout the in-life phase of a study.